Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Elutia Inc. Class A Common Stock

ELUT

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Last trade $0.8373
Day change +$0.0144 (+1.75%)
Day range $0.7982 – $0.892
Volume 40,318
Market cap $37M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$36.41M
Price / earnings
0.67×
Price / book
2.38×
Price / sales
3.66×
EV / sales
1.55×
EV / EBITDA
-0.68×

Profitability

Earnings per share
$1.23
Return on assets
112.86%
Return on equity
354.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.53×
Current ratio
2.63×
Quick ratio
2.61×
Cash ratio
1.81×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$50.68M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ELUT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.14M$2.43M$3.11M$3.27M$944K$2.75M$2.95M$2.82M
Cost of revenue$435K$980K$1.31M$1.36M$446K$1.29M$1.57M$1.49M
Gross profit$702K$1.45M$1.8M$1.91M$498K$1.45M$1.38M$1.32M
Selling, general and administrative$4.5M$4.82M$5.57M$6.19M$4.43M$4.83M$4.72M$5.44M
Research and development$2.98M$2.53M$1.97M$1.22M$1.09M$989K$871K$727K
Total operating expenses$7.6M$9.4M$8.15M$8.48M$6.37M$9.82M$8.16M$8.78M
Operating income-$6.9M-$7.96M-$6.35M-$6.56M-$5.87M-$8.37M-$6.78M-$7.46M
Interest expense-$278K$35K$0-$42K-$265K$491K$0$796K
Income before taxes-$6.5M-$7.64M-$7.82M-$6.52M-$1.04M-$7.08M-$1.88M-$7.15M
Income taxes$8K$8K$70K-$11K$8K$8K$8K$2K
Net income-$1.29M-$7.65M-$7.47M$70.79M-$3.87M-$9.61M-$3.93M-$9.06M
Net income attributable to common shareholders-$1.29M-$7.65M-$7.47M$70.79M-$3.87M-$9.61M-$3.93M-$9.06M
EBITDA-$6.38M-$5.55M-$5.41M-$5.19M-$4.29M-$3.47M-$3.34M-$3.98M
Basic earnings per share-$0.03-$0.17-$0.17$1.65-$0.09-$0.23-$0.10-$0.26
Diluted earnings per share-$0.04-$0.17-$0.17$1.49-$0.19-$0.26-$0.21-$0.28

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. (Nasdaq: ELUT) announced the grant of 460,000 non-qualified stock options to three new employees as inducement awards on March 10, 2026, with an exercise price of $1.09 per share. The options vest 25% after one year, with the remainder vesting monthly over three years, subject to continued employment.

GlobeNewswire Inc.

Elutia Announces $13.26 Million Registered Direct Offering

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.